Elekta (EKTAY) Stock Price, News & Analysis

Company Overview

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment. Elekta also provides oncology information systems and treatment planning software that enable seamless integration of imaging, planning and delivery for multidisciplinary clinical teams. In addition, the company offers comprehensive service and support programs, clinical training and educational resources to ensure optimal system performance and professional development for its customers.

Founded in 1972 by Swedish neurosurgeon Lars Leksell, Elekta pioneered stereotactic radiosurgery and has since grown into a worldwide provider of precision cancer care technologies. Headquartered in Stockholm, Sweden, the company serves hospitals, cancer centers and clinics across Europe, North America, Asia-Pacific, Latin America, the Middle East and Africa. Elekta maintains regional offices and service centers to support installation, maintenance and training programs in key markets around the globe.

Guided by a leadership team of experienced executives and a board of directors with deep expertise in healthcare technology, Elekta continues to invest in research and development to advance treatment efficacy and patient quality of life. The company collaborates with academic institutions, clinical partners and industry stakeholders to drive innovation in radiotherapy and radiosurgery and to shape the future of precision cancer care.

Key Stats

• Today's Range: $6.05 to $6.05
• 50-Day Range: $5.66 to $6.69
• 52-Week Range: $4.35 to $6.93
• Volume: 84 shs
• Average Volume: 620 shs
• Market Capitalization: $2.23 billion
• P/E Ratio: N/A
• Dividend Yield: 2.15%
• Price Target: N/A
• Consensus Rating: Reduce

Elekta Stock Analysis - MarketRank™

Elekta scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Elekta has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Elekta has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.82%

Earnings Growth

Earnings for Elekta are expected to grow by 12.82% in the coming year, from $0.39 to $0.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elekta is -603.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elekta is -603.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elekta has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Elekta has been sold short.

Short Interest Ratio / Days to Cover

Elekta has a short interest ratio ("days to cover") of 0.51, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elekta has recently decreased by 53.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Elekta pays a meaningful dividend of 2.15%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Elekta does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Elekta will have a dividend payout ratio of 29.55% next year. This indicates that Elekta will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.50

News Sentiment

Elekta has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Elekta this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elekta insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.28% of the stock of Elekta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Elekta has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 3/05/2026
• Today: 5/15/2026
• Next Earnings (Estimated): 5/27/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EKTAY
• CIK: 1451160
• Web: www.elekta.com
• Phone: (685) 872-5400
• Fax: 46-8-587-255-00
• Employees: 4,556
• Year Founded: 1972

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 15.50
• P/E Growth: N/A
• Net Income: $22.37 million
• Net Margins: -0.08%
• Pretax Margin: 1.10%
• Return on Equity: 12.84%
• Return on Assets: 3.88%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 0.95
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $1.71 billion
• Price / Sales: 1.30
• Cash Flow: $0.61 per share
• Price / Cash Flow: 9.88
• Book Value: $2.19 per share
• Price / Book: 2.76

Miscellaneous

• Outstanding Shares: 368,590,000
• Free Float: 216,435,000
• Market Cap: $2.23 billion
• Optionable: Not Optionable
• Beta: 1.01